| Species |
Human |
| Protein Construction |
| hFc |
IGFII (Ala25-Glu91)
Accession # P01344-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human IGFBP3, His Tag at 5μg/ml (100μl/well) on the plate can bind IGFII hFc Chimera, Human. Test result was comparable to standard batch |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
33.00 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 35-45 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The insulin family consists of insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), their receptors (IR, IGF-1R and IGF-2R), and their binding proteins. All three ligands are involved in cell proliferation, apoptosis, protein synthesis and metabolism due to their homologous sequences and structural similarities. Insulin-like growth factor 2, a member of the insulin family, plays an important role in embryonic development, metabolic disorders, and tumorigenesis by combining with three receptors with different degrees of affinity. |
| Synonyms |
IGF-II; Somatomedin-A; Somatomedin A; IGF2; PP1446 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
